CTOs on the Move

Rakuten Medical

www.rakuten-med.com

 
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company`s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
John Childs
 Sr. Director of Information Systems and Information Security Profile

Funding

Rakuten Medical raised $100M on 08/01/2019

Similar Companies

Pronutria

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.

Chi Scientific

Chi Scientific is a Maynard, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Insight

Health Insight is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entelo

Entelo applies intelligence to big data to help modern recruiters identify, qualify and engage talent. Today, more than 700 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights and increased productivity. The leader in recruiting automation, Entelo helps organizations like Capital One, Cisco, GE, Genentech, Netflix, Northrop Grumman and Target build their teams.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.